The antiviral drug remdesivir is showing promise against the coronavirus. Preliminary results from a clinical trial from the National Institutes of Health found patients taking the experimental drug recovered an average of four days sooner than those on a placebo.Dr. Anthony Fauci called the results “a very important proof of concept that a drug can block this virus,” and the Food and Drug Administration may now consider an emergency approval to broaden its use. But, there are also reasons to be cautious and the drug is not a cure.One patient in the study spoke to CBS News senior medical correspondent Dr. Tara Narula about his experience.”It was a very quick onset,” Drew McDonald said about the virus. “It got real for me when I laid down Sunday night and couldn’t breathe.”McDonald’s battle against COVID-19 had just landed him in the hospital when doctors asked the 29-year-old to join a clinical trial of remdesivir.He was already getting intravenous medication for double pneumonia. “So I thought, you know, ‘Why not? Absolutely,'” he said.”By the time I left the hospital, I was already improving drastically,” McDonald said.McDonald was one of more than 1,000 hospitalized COVID-19 patients in the nationwide trial. Those receiving remdesivir

Continue To Full Article